Amsterdam Molecular Therapeutics Reports Half Year Re...(UR 25million compared to EUR 34 million ...)

"AMT showed important results in the first half of 2009. We presented additional data showing the clinically important health benefit of our lead product, Glybera(R), while good progress was made in the further development of our pipeline-products and the strengthening of the company. The search process for a new permanent CEO is progressing expeditiously but carefully to ensure the engagement of a capable new CEO. All of this reinforces our position as a leader in gene therapy and gives us a strong foundation for further growth," said Sander van Deventer, CEO of AMT.

Conference call and webcast presentation

AMT will conduct a conference call open to the public today at 2.00 p.m. CET, which will also be webcast. Netherlands dial in: +31 800 949 4517 (toll free); US dial in: +1 866 291 4166 (toll free); UK dial in: +44 800 279 3 39 56 (toll free). To listen to the conference call live via the internet, visit the investor relations portion of the AMT website at http://www.amtbiopharma.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software. Playback of the call will be availably for 24 hours after the call. Dial In: +41 91 612 4330; +44 20 7108 6233; or +1 866 416 2558. The archived webcast also will be available for replay shortly after the close of the call.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and sc
'/>"/>